LI.FI has integrated a Solana blockchain route for Ondo Finance’s tokenized U.S. stocks and ETFs, which were previously accessible on Ethereum and BNB Chain. This expansion allows more users through compatible services to access these tokenized assets, although eligibility and operator support are required. Ondo’s tokenized products provide exposure to U.S.-listed securities for investors outside the U.S., with over $1.3 billion in total value locked. The integration broadens LI.FI’s network, which connects over 1,000 apps, wallets, fintechs, and neobanks, but does not enable direct access for U.S. clients.
LI.FI's integration of a Solana route for Ondo tokenized stocks and ETFs provides context for digital asset market activity. For readers following cryptocurrency trends, here is Pluang's market snapshot as of Oct 20, 2026 06:02 WIB: out of 50 major cryptocurrencies, 42 rose and 7 fell. Notable movers include BAT at Rp3.487 with a 1-day change of +11.96%, BAL at Rp16.297 with +11.14%, and EOS at Rp12.649 with +8.13%.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
